Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases

Autoimmunity Reviews

Volumn 13, Issue 3, 2014, Pages 272-280

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Giuggioli, Dilia ^b   Ferrannini, Ele ^a   Ferri, Clodoveo ^b   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Autoimmune thyroiditis; Circulating CXCL10 levels; Cryoglobulinemia; CXCL10; CXCR3; Graves; Graves' disease; Graves' ophthalmopathy; Hepatitis C virus infection associated mixed cryoglobulinemia; IP 10; Juvenile idiopathic arthritis; Papillary thyroid cancer; Peroxisome proliferator activated receptor ; Psoriatic arthritis; Rheumatoid arthritis; Sj gren syndrome; Systemic lupus erythematosus; Systemic sclerosis; Thyroid follicular cells; Thyroiditis; Toxic nodular goiter; Type 1 diabetes

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; CRYOGLOBULINEMIA; CYTOKINE RELEASE; ENDOCRINE OPHTHALMOPATHY; GRAVES DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; NATURAL KILLER CELL; NATURAL KILLER T CELL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

AT; AUTOIMMUNE THYROIDITIS; CCL; CD; CEREBROSPINAL FLUID; CHEMOKINE (C-C MOTIF) LIGAND; CHEMOKINE (C-X-C MOTIF) LIGAND; CHEMOKINE (C-X-C MOTIF) RECEPTOR 3; CIA; CIRCULATING CXCL10 LEVELS; CLUSTER OF DIFFERENTIATION; COLLAGEN-INDUCED ARTHRITIS; CORTICOSTEROID; CRYOGLOBULINEMIA; CS; CSF; CXCL; CXCL10; CXCR3; GAD; GD; GLUTAMIC ACID DECARBOXYLASE; GO; GRAVES; GRAVES' DISEASE; GRAVES' OPHTHALMOPATHY; GTX; HEPATITIS C VIRUS INFECTION ASSOCIATED MIXED CRYOGLOBULINEMIA; HYPERTHYROID GD; IFN; IFN-Γ-INDUCED PROTEIN 10; IL; INTERFERON; INTERLEUKIN; IP-10; JIA; JUVENILE IDIOPATHIC ARTHRITIS; MACROPHAGE-DERIVED CHEMOKINE/CCL22; MC; MC+HCV; MCP-1; MDC/CCL22; METHIMAZOLE; METHYLPREDNISOLONE; MIG; MIXED CRYOGLOBULINEMIA; MMI; MONOCYTE CHEMOTACTIC PROTEIN-1; MONOKINE INDUCED BY IFN-Γ; MP; NATURAL KILLER; NEUROPSYCHIATRIC SLE; NF-KB; NK; NORMAL T CELL EXPRESSED AND SECRETED; NPSLE; NUCLEAR FACTOR-KAPPA B; PAPILLARY THYROID CANCER; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Γ; PPAR-Γ; PSA; PSORIATIC ARTHRITIS; PTC; RA; RANKL; RANTES; REARRANGED IN TRANSFORMATION/PTC; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B LIGAND; RET/PTC; RHEUMATOID ARTHRITIS; SCXCL10; SF; SJÖGREN SYNDROME; SLE; SS; SSC; ST; SYNOVIAL FLUID; SYNOVIAL TISSUE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T HELPER; T1D; TARC/CCL17; TELERADIOTHERAPY; TFC; TH; THYMUS AND ACTIVATION REGULATED CHEMOKINE/CCL17; THYROID FOLLICULAR CELLS; THYROIDITIS; TNF; TNG; TOXIC NODULAR GOITER; TR; TUMOR NECROSIS FACTOR; TYPE 1 DIABETES;

ANIMALS; AUTOIMMUNE DISEASES; CHEMOKINE CXCL10; HUMANS; INFLAMMATION; LIGANDS; RECEPTORS, CXCR3;

EID: 84891738394     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.10.010     Document Type: Review

References (144)

1. Belperio J.A., Keane M.P., Arenberg D.A., Addison C.L., Ehlert J.E., Burdick M.D., et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000, 68:1-8.
2. Engel M.A., Neurath M.F. Anticancer properties of the IL-12 family-focus on colorectal cancer. Curr Med Chem 2010, 17:3303-3308.
3. Antonelli A., Ferri C., Ferrari S.M., Colaci M., Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008, 8:18-23.
4. Lee E.Y., Lee Z.H., Song Y.W. CXCL10 and autoimmune diseases. Autoimmun Rev 2009, 8:379-383.
5. Barbeau W.E. What is the key environmental trigger in type 1 diabetes-is it viruses, or wheat gluten, or both?. Autoimmun Rev 2012, 12:295-299.
6. Askenasy E.M., Askenasy N. Is autoimmune diabetes caused by aberrant immune activity or defective suppression of physiological self-reactivity?. Autoimmun Rev 2013, 12:633-637.
7. Lo J., Clare-Salzler M.J. Dendritic cell subsets and type I diabetes: focus upon DC-based therapy. Autoimmun Rev 2006, 5:419-423.
8. Shimada A., Morimoto J., Kodama K., Suzuki R., Oikawa Y., Funae O., et al. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 2001, 24:510-515.
9. Nicoletti F., Conget I., Di Mauro M., Di Marco R., Mazzarino M.C., Bendtzen K., et al. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002, 45:1107-1110.
10. Nakagawa Y., Shimada A., Oikawa Y., Irie J., Shigihara T., Tsumura K., et al. Two cases of "fulminant" type 1 diabetes suggesting involvement of autoimmunity. Ann N Y Acad Sci 2003, 1005:359-361.
11. Gabbay M.A., Sato M.N., Duarte A.J., Dib S.A. Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clin Exp Immunol 2012, 168:60-67.
12. Rotondi M., Romagnani P., Brozzetti A., Santeusanio F., Serio M., Falorni A., et al. Serum concentrations of the interferon-alpha-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002, 45:1107-1110.
13. Diabetologia 2003, 46:1020-1021.
14. Hanifi-Moghaddam P., Kappler S., Seissler J., Müller-Scholze S., Martin S., Roep B.O., et al. Altered chemokine levels in individuals at risk of type 1 diabetes mellitus. Diabet Med 2006, 23:156-163.
15. Antonelli A., Fallahi P., Ferrari S.M., Pupilli C., d'Annunzio G., Lorini R., et al. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med 2008, 25:1349-1353.
16. Shanmugam N., Ransohoff R.M., Natarajan R. Interferon-gamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100b. J Biol Chem 2006, 281:31212-31221.
17. Rosa J.S., Mitsuhashi M., Oliver S.R., Ogura M., Flores R.L., Pontello A.M., et al. Ex vivo TCR-induced leukocyte gene expression of inflammatory mediators is increased in type 1 diabetic patients but not in overweight children. Diabetes Metab Res Rev 2010, 26:33-39.
18. Frigerio S., Junt T., Lu B., Gerard C., Zumsteg U., Holländer G.A., et al. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 2002, 8:1414-1420.
19. Roep B.O., Kleijwegt F.S., van Halteren A.G., Bonato V., Boggi U., Vendrame F., et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol 2010, 159:338-343.
20. Uno S., Imagawa A., Saisho K., Okita K., Iwahashi H., Hanafusa T., et al. Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes. Endocr J 2010, 57:991-996.
21. Shigihara T., Shimada A., Oikawa Y., Yoneyama H., Kanazawa Y., Okubo Y., et al. CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced beta cell proliferation in NOD mice. J Immunol 2005, 175:8401-8408.
22. Tozzoli R., Barzilai O., Ram M., Villalta D., Bizzaro N., Sherer Y., et al. Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 2008, 8:112-115.
23. Burek C.L., Rose N.R. Autoimmune thyroiditis and ROS. Autoimmun Rev 2008, 7:530-537.
24. Garcià-Lòpez M.A., Sancho D., Sànchez-Madrid F., Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 2001, 86:5008-5016.
25. Kemp E.H., Metcalfe R.A., Smith K.A., Woodroofe M.N., Watson P.F., Weetman A.P. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol 2003, 59:207-213.
26. Kimura H., Kimura M., Rose N.R., Caturegli P. Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto's thyroiditis. Exp Mol Pathol 2004, 77:161-167.
27. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Buonamano A., et al. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004, 89:5496-5499.
28. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Paolicchi A., et al. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 2005, 152:171-177.
29. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Frascerra S., Sebastiani M., et al. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 2008, 42:137-143.
30. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Frascerra S., Carpi A., et al. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism 2008, 57:1270-1277.
31. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Frascerra S., Pampana A., et al. CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. J Interferon Cytokine Res 2009, 29:345-351.
32. Antonelli A., Fallahi P., Delle Sedie A., Ferrari S.M., Maccheroni M., Bombardieri S., et al. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity 2008, 41:537-542.
33. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Sebastiani M., Ferrari D., et al. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 2008, 103:2488-2494.
34. Antonelli A., Ferri C., Fallahi P., Colaci M., Giuggioli D., Ferrari S.M., et al. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol 2008, 35:1809-1811.
35. Antonelli A., Ferri C., Ferrari S.M., De Marco S., Di Domenicantonio A., Centanni M., et al. Interleukin-1β, C-X-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. J Interferon Cytokine Res 2010, 30:835-842.
36. Antonelli A., Ferri C., Ferrari S.M., Colaci M., Sansonno D., Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 2009, 5:26-34.
37. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Romagnani P., Grosso M., et al. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006, 154:651-658.
38. Antonelli A., Ferrari S.M., Frascerra S., Galetta F., Franzoni F., Corrado A., et al. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine 2011, 55:288-293.
39. Antonelli A., Fallahi P., Ferrari S.M., Sebastiani M., Manfredi A., Mazzi V., et al. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod Rheumatol 2012, 22:659-667.
40. Antonelli A., Ferri C., Ferrari S.M., Frascerra S., Ruffilli I., Caponi L., et al. High levels of circulating chemokine (C-X-C motif) ligand 11 are associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis and with chemokine (C-X-C motif) ligand 10. J Interferon Cytokine Res 2012, 32:74-80.
41. Groom J.R., Luster A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011, 89:207-215.
42. Antonelli A., Rotondi M., Ferrari S.M., Fallahi P., Romagnani P., Franceschini S.S., et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006, 91:614-620.
43. Rotondi M., Coperchini F., Pignatti P., Sideri R., Groppelli G., Leporati P., et al. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation?. J Clin Endocrinol Metab 2013, 98:308-313.
44. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Santini E., Franceschini S.S., et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009, 94:1803-1809.
45. Lytton S.D., Kahaly G.J. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev 2010, 10:116-122.
46. Tozzoli R., Bagnasco M., Giavarina D., Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev 2012, 12:107-113.
47. Mariotti S., Del Prete G.F., Mastromauro C., De Carli M., Romagnani S., Ricci M., et al. The autoimmune infiltrate of Basedow's disease: analysis of clonal level and comparison with Hashimoto's thyroiditis. Exp Clin Endocrinol 1991, 97:139-146.
48. Romagnani P., Rotondi M., Lazzeri E., Lasagni L., Francalanci M., Buonamano A., et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 2002, 161:195-206.
49. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Barani L., et al. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol 2006, 64:189-195.
50. Ashhab Y., Dominguez O., Sospedra M., Roura-Mir C., Lucas-Martin A., Pujol-Borrell R. A one-tube polymerase chain reaction protocol demonstrates CC chemokine overexpression in Graves' disease glands. J Clin Endocrinol Metab 1999, 84:2873-2882.
51. Aust G., Sittig D., Becherer L., Anderegg U., Schutz A., Lamesch P., et al. The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases. Eur J Endocrinol 2004, 150:225-234.
52. Armengol M.P., Juan M., Lucas-Martin A., Fernandez-Figueras M.T., Jaraquemada D., Gallart T., et al. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol 2001, 159:861-873.
53. Siddiqi A., Monson J.P., Wood D.F., Besser G.M., Burrin J.M. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 1999, 84:435-439.
54. Domberg J., Liu C., Papewalis C., Pfleger C., Xu K., Willenberg H.S., et al. Circulating chemokines in patients with autoimmune thyroid diseases. Horm Metab Res 2008, 40:416-421.
55. Inukai Y., Momobayashi A., Sugawara N., Aso Y. Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. Eur J Endocrinol 2007, 156:623-630.
56. Crescioli C., Cosmi L., Borgogni E., Santarlasci V., Gelmini S., Sottili M., et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 2007, 195:145-155.
57. Brück P., Bartsch W., Sadet D., Penna-Martinez M., Kurylowicz A., Bednarczuk T., et al. A CXC motif ligand 10 polymorphism as a marker to predict severity of Graves' disease. Thyroid 2010, 20:343-345.
58. Sakai H., Togawa Y., Fukuda G., Ito R., Miwa T., Odawara M. Serum chemokine (C-X-C motif) ligand 10 levels are elevated in patients with Graves' disease in long-term remission. Thyroid 2010, 20:341-342.
59. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Serio M., Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006, 93:1226-1231.
60. Antonelli A., Rotondi M., Fallahi P., Grosso M., Boni G., Ferrari S.M., et al. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 2007, 92:1485-1490.
61. Leite A.C., Pedro A.B.., Romaldini J.H. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease. Horm Metab Res 2011, 43:194-199.
62. Dong Q.Y., Li S.J., Gao G.Q., Liu X.M., Li W.X., Liang C.G., et al. Short-term effect of radioactive iodine therapy on CXCL-10 production in Graves' disease. Clin Invest Med 2011, 34:E262.
63. Mysliwiec J., Palyga I., Kosciuszko M., Kowalska A., Gorska M. Circulating CXCL9 and CXCL10 as markers of activity of Graves' orbitopathy during treatment with corticosteroids and teleradiotherapy. Horm Metab Res 2012, 44:957-961.
64. Proudfoot A.E., Power C.A., Rommel C., Wells T.N. Strategies for chemokine antagonists as therapeutics. Semin Immunol 2003, 15:57-65.
65. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000, 164:6503-6508.
66. Gosset P., Charbonnier A.S., Delerive P., Fontaine J., Staels B., Pestel J., et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 2001, 31:2857-2865.
67. Schaefer K.L., Denevich S., Ma C., Cooley S.R., Nakajima A., Wada K., et al. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 2005, 11:244-252.
68. Antonelli A., Ferrari S.M., Fallahi P., Piaggi S., Paolicchi A., Franceschini S.S., et al. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism 2011, 60:277-283.
69. Spencer N.F., Poynter M.E., Im S.Y., Daynes R.A. Constitutive activation of NF-kappa B in an animal model of aging. Int Immunol 1997, 9:1581-1588.
70. Oliveira A.C., Bertollo C.M., Rocha L.T., Nascimento E.B., Costa K.A., Coelho M.M. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol 2007, 561:194-201.
71. Lee J.W., Bajwa P.J., Carson M.J., Jeske D.R., Cong Y., Elson C.O., et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10 deficient mice. Gastroenterology 2007, 133:108-123.
72. Antonelli A., Ferrari S.M., Frascerra S., Corrado A., Pupilli C., Bernini G., et al. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. Exp Cell Res 2011, 317:1527-1533.
73. Delerive P., De Bosscher K., Besnard S., Vanden Bergh W., Peters J.M., Gonzalez F.J., et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274:32048-32054.
74. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
75. Yin Z., Siegert S., Neure L., Grolms M., Liu L., Eggens U., et al. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology (Oxford) 1999, 38:1058-1067.
76. Lee E.Y., Lee Z.H., Song Y.W. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev 2013, 12:554-557.
77. Hanaoka R., Kasama T., Muramatsu M., Yajima N., Shiozawa F., Miwa Y., et al. A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 2003, 5:R74-R81.
78. Kwak H.B., Ha H., Kim H.N., Lee J.H., Kim H.S., Lee S., et al. Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 2008, 58:1332-1342.
79. Wedderburn L.R., Robinson N., Patel A., Varsani H., Woo P. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2000, 43:765-774.
80. Ruth J.H., Rottman J.B., Katschke K.J., Qin S., Wu L., LaRosa G., et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001, 44:2750-2760.
81. Yellin M., Paliienko I., Balanescu A., Ter-Vartanian S., Tseluyko V., Xu L.A., et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64:1730-1739.
82. Silverman E.D., Isacovics B., Petsche D., Laxer R.M. Synovial fluid cells in juvenile arthritis: evidence of selective T cell migration to inflamed tissue. Clin Exp Immunol 1993, 91:90-95.
83. Pharoah D.S., Varsani H., Tatham R.W., Newton K.R., de Jager W., Prakken B.J., et al. Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells. Arthritis Res Ther 2006, 8:R50.
84. Antonelli A., Fallahi P., Delle Sedie A., Ferrari S.M., Maccheroni M., Bombardieri S., et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthritis. Clin Exp Rheumatol 2009, 27:22-27.
85. Hueber W., Tomooka B.H., Zhao X., Kidd B.A., Drijfhout J.W., Fries J.F., et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007, 66:712-719.
86. Funauchi M., Ikoma S., Enomoto H., Horiuchi A. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. Scand J Rheumatol 1998, 27:219-224.
87. Prud'homme G.J., Kono D.H., Theofilopoulos A.N. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-10 and interferon gamma mRNA in the lymph nodes of lupus-prone mice. Mol Immunol 1995, 32:495-503.
88. Flier J., Boorsma D.M., van Beek P.J., Nieboer C., Stoof T.J., Willemze R., et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001, 194:398-405.
89. Wenzel J., Wörenkämper E., Freutel S., Henze S., Haller O., Bieber T., et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005, 205:435-442.
90. Meller S., Winterberg F., Gilliet M., Müller A., Lauceviciute I., Rieker J., et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005, 52:1504-1516.
91. Gambichler T., Genc Z., Skrygan M., Scola N., Tigges C., Terras S., et al. Cytokine and chemokine ligand expression in cutaneous lupus erythematosus. Eur J Dermatol 2012, 22:319-323.
92. Narumi S., Takeuchi T., Kobayashi Y., Konishi K. Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 2000, 12:1561-1565.
93. Lit L.C., Wong C.K., Tam L.S., Li E.K., Lam C.W. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006, 65:209-215.
94. Toledano P., Sarbu N., Espinosa G., Bargalló N., Cervera R. Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 2013, 12:1166-1170.
95. Sciascia S., Bertolaccini M.L., Baldovino S., Roccatello D., Khamashta M.A., Sanna G. Central nervous system involvement in systemic lupus erythematosus: overview on classification criteria. Autoimmun Rev 2013, 12:426-429.
96. Fragoso-Loyo H., Richaud-Patin Y., Orozco-Narvaez A., Davila-Maldonado L., Atisha-Fregoso Y., Llorente L., et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007, 56:1242-1250.
97. Brey R.L., Holliday S.L., Saklad A.R., Navarrete M.G., Hermosillo-Romo D., Stallworth C.L., et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002, 58:1214-1220.
98. Reyes-Thomas J., Blanco I., Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 2011, 40:138-150.
99. Wu Q., Yang Q., Lourenco E., Sun H., Zhang Y. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther 2011, 13:R88.
100. Giuggioli D., Manfredi A., Colaci M., Manzini C.U., Antonelli A., Ferri C. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev 2013, 12:1058-1063.
101. Ferri C., Zignego A.L. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr Opin Rheumatol 2000, 12:53-60.
102. Zignego A.L., Ferri C., Giannelli F., Giannini C., Caini P., Monti M., et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002, 137:571-580.
103. Ferri C., Pileri S., Zignego A.L. Hepatitis C virus infection and in non-Hodgkin's lymphoma. Infectious causes of cancer. Targets for intervention 2000, 349-368. The Human Press Inc., Totowa, New Jersey. J. Goedert (Ed.).
104. Giannelli F., Moscarella S., Giannini C., Caini P., Monti M., Gragnani L., et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 2003, 102:1196-1201.
105. Saadoun D., Boyer O., Trébeden-Nègre H., Limal N., Bon-Durand V., Andreu M., et al. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. J Hepatol 2004, 41:1031-1037.
106. Loffreda S., Muratori P., Muratori L., Miele L., Bianchi F.B., Lenzi M. Enhanced monocyte Th1 cytokine production in HCV-infected cryoglobulinemic patients. J Hepatol 2003, 38:230-236.
107. Patzwahl R., Meier V., Ramadori G., Mihm S. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization. J Virol 2001, 75:1332-1338.
108. Mihm S., Schweyer S., Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J Med Virol 2003, 70:562-570.
109. Matskevich A.A., Strayer D.S. Exploiting hepatitis C virus activation of NFkappaB to deliver HCV-responsive expression of interferons alpha and gamma. Gene Ther 2003, 10:1861-1873.
110. Murata M., Nabeshima S., Maeda N., Nakashima H., Kashiwagi S., Hayashi J. Increased frequency of IFN-gamma-producing peripheral CD8+ T cells with memory-phenotype in patients with chronic hepatitis C. J Med Virol 2002, 67:162-170.
111. Itoh Y., Morita A., Nishioji K. Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels. J Viral Hepat 2001, 8:341-348.
112. Antonelli A., Ferri C., Galeazzi M., Giannitti C., Manno D., Mieli-Vergani G., et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 2008, 26:S39-S47.
113. Antonelli A., Ferri C., Fallahi P. Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol 2009, 6:633-635.
114. Apolinario A., Majano P.L., Lorente R., Nuñez O., Clemente G., Garcia-Monzòn C. Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins. J Viral Hepat 2005, 12:27-37.
115. Antonelli A., Ferri C., Ferrari S.M., Ruffilli I., Colaci M., Frascerra S., et al. High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-γ. J Rheumatol 2011, 38:1947-1952.
116. Antonelli A., Ferri C., Ferrari S.M., Ghiri E., Marchi S., Sebastiani M., et al. Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. J Rheumatol 2010, 37:91-97.
117. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Frascerra S., Franzoni F., et al. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. Dig Liver Dis 2009, 41:42-48.
118. Antonelli A., Miccoli P., Derzhitski V.E., Panasiuk G., Solovieva N., Baschieri L. Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). World J Surg 1996, 20:867-871.
119. Spinelli C., Bertocchini A., Antonelli A., Miccoli P. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients
120. Antonelli A., Ferri C., Fallahi P. Thyroid cancer in patients with hepatitis C infection. JAMA 1999, 281:1588.
121. Montella M., Crispo A., Pezzullo L., Izzo F., Fabbrocini G., Ronga D., et al. Is hepatitis C virus infection associated with thyroid cancer? A case-control study. Int J Cancer 2000, 87:611-612.
122. Montella M., Crispo A., de Bellis G., Izzo F., Frigeri F., Ronga D., et al. HCV and cancer: a case-control study in a high-endemic area. Liver 2001, 21:335-341.
123. Antonelli A., Ferri C., Fallahi P., Nesti C., Zignego A.L., Maccheroni M. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol 2002, 20:693-696.
124. Fiore E., Rago T., Latrofa F., Provenzale M.A., Piaggi P., Delitala A., et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer 2011, 18:429-437.
125. Antonelli A., Ferri C., Fallahi P., Pampana A., Ferrari S.M., Barani L., et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007, 17:447-451.
126. Ferri C., Antonelli A., Mascia M.T., Sebastiani M., Fallahi P., Ferrari D., et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007, 39:S13-S21.
127. Neri S., Antonelli A., Falaschi F., Boraschi P., Baschieri L. Findings from high resolution computed tomography of the lung and pleura of symptom free workers exposed to amosite who had normal chest radiographs and pulmonary function tests. Occup Environ Med 1994, 51:239-243.
128. Antonelli A., Bocci G., La Motta C., Ferrari S.M., Fallahi P., Fioravanti A., et al. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab 2011, 96:E288-E296.
129. Antonelli A., Fallahi P., Ferrari S.M., Carpi A., Berti P., Materazzi G., et al. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother 2008, 62:559-563.
130. Melillo R.M., Castellone M.D., Guarino V., De Falco V., Cirafici A.M., Salvatore G., et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005, 115:1068-1081.
131. Puxeddu E., Knauf J.A., Sartor M.A., Mitsutake N., Smith E.P., Medvedovic M., et al. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr Relat Cancer 2005, 12:319-334.
132. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Piaggi S., Gelmini S., et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer 2009, 16:1299-1311.
133. Fauchais A.L., Martel C., Gondran G., Lambert M., Launay D., Jauberteau M.O., et al. Immunological profile in primary Sjögren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev 2010, 9:595-599.
134. Hasegawa M., Inoue A., Kohno M., Muraoka M., Miyazaki T., Terada M., et al. Antagonist of interferon-inducible protein 10/CXCL10 ameliorates the progression of autoimmune sialadenitis in MRL/lpr mice. Arthritis Rheum 2006, 54:1174-1183.
135. Elhai M., Avouac J., Kahan A., Allanore Y. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev 2013, 12:1052-1057.
136. Fujii H., Shimada Y., Hasegawa M., Takehara K., Sato S. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 2004, 35:43-51.
137. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Giuggioli D., Colaci M., et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford) 2008, 47:45-49.
138. Tiev K.P., Chatenoud L., Kettaneh A., Tolédano C., Bach J.F., Cabane J. Increase of CXCL10 serum level in systemic sclerosis interstitial pneumonia. Rev Med Interne 2009, 30:942-946.
139. Hasegawa M., Fujimoto M., Matsushita T., Hamaguchi Y., Takehara K., Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011, 30:231-237.
140. Antonelli A., Fallahi P., Ferrari S.M., Giuggioli D., Colaci M., Di Domenicantonio A., et al. Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2. J Rheumatol 2012, 39:979-985.
141. Rabquer B.J., Tsou P.S., Hou Y., Thirunavukkarasu E., Haines G.Z., Impens A.J., et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 2011, 13:R18.
142. Antonelli A., Ferri C., Ferrari S.M., Colaci M., Giuggioli D., Fallahi P. Induction of CXCL10 secretion by interferon-γ and tumour necrosis factor-α and its inhibition by peroxisome proliferator-activated receptor-γ agonists in cultured scleroderma fibroblasts. Br J Dermatol 2010, 163:650-651.
143. Hasegawa M., Asano Y., Endo H., Fujimoto M., Goto D., Ihn H., et al. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol Nov. 23 2012, [Epub ahead of print].
144. Liu X., Mayes M.D., Tan F.K., Wu M., Reveille J.D., Harper B.E., et al. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum 2013, 65:226-235.